2008
October 2, 2008 - Alba Therapeutics Announces Promotions
May 20, 2008 - Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
May 16, 2008 - Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
April 3, 2008 - Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
March 18, 2008 - Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
January 18, 2008 - Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
2007
December 14, 2007 - Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
September 19, 2007 - Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
September 7, 2007 - Alba Therapeutics Appoints Dr. Betsy Van Parijs as its Senior Vice President, Clinical Development and Medical Affairs
September 5, 2007 - Alba Therapeutics Announces Clearance of IND for Beta Cell Preservation in Type 1 Diabetes using AT-1001
May 7, 2007 - Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease. Announces Plans for Advancing AT-1001 into Later Stage Clinical Trials
May 4, 2007 - Alba Therapeutics Corporation to Present at the BIO 2007 Business Forum
April 16, 2007 - Alba Announces Appointment of Chief Financial Officer
March 08, 2007 - Alba Announces Completion of Enrollment and Dosing of Patients in Phase II Clinical Trial of AT-1001 for the Treatment of Celiac Disease
March 05, 2007 - Alba Therapeutics Appoints Dr. Linda Arterburn to Head Pharmacology and Toxicology Department
January 09, 2007 - Baltimore - Alba Therapeutics Appoints Dr. Sefik S. Alkan to Lead Discovery Efforts
2006
November 27, 2006 - Alba Therapeutics Corporation Announces $10 million in Financing
November 20, 2006 - Alba Therapeutics Corporation to Present at the Piper Jaffray Healthcare Conference
November 10, 2006 - Alba Therapeutics Presents Data from Positive Phase Ib Clinical Trial at the XII International Celiac Disease Symposium
October 30, 2006 - Alba Therapeutics Corporation and The Royal Veterinary College, London Announce Initiation of AT-1001 Study in Patient Dogs with Inflammatory Bowel Disease
September 21, 2006 - Alba Therapeutics Announces Phase II Trial for Zonulin Antagonist AT-1001
August 10, 2006 - Alba Therapeutics Appoints Allen to Head Legal Department
July 27, 2006 - Alba Therapeutics announced today the hiring of Stuart D. Sedlack as Senior Vice President, Corporate Development
April 03, 2006 - Alba Therapeutics Corporation Completes Phase I for AT-1001
March 13, 2006 - Alba Therapeutics Announces Positive Phase Ib Clinical Trial Results
March 06, 2006 - Alba Therapeutics Announces Creation of Development Advisory Board
February 21, 2006 - Alba Therapeutics Announces New Federal and State Grant Awards